Clinical Trials Logo

Clinical Trial Summary

The manufacturers of AlphaBRAIN(TM) claim that their product, when taken as directed, has beneficial effects on cognition. The active ingredient in AlphaBRAIN, Huperzine A, is a naturally occurring compound found in firmoss and also thought to be an acetylcholinesterase inhibitor. Numerous clinical studies have been undertaken to investigate the effects of Huperzine A on cognition and have demonstrated benefit to cognition in both individuals diagnosed with neurodegenerative diseases as well as performance on academic tasks by students. However, to our knowledge, there are no randomized controlled trials evaluating the effects of AlphaBRAIN(TM) on cognition. Thus, the purpose of the current study is to assess the effects of daily oral administration of AlphaBRAIN(TM) on cognitive functioning, as compared to placebo, after 45 days of treatment.

1. To evaluate a single daily dose of AlphaBRAIN(TM) vs placebo given orally on the change in a battery of standardized neuropsychological tests (see attached).

2. A secondary objective is to evaluate a single daily dose of AlphaBRAIN(TM) vs placebo given orally on sleep.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02739139
Study type Interventional
Source Onnits Labs, LLC
Contact
Status Completed
Phase Phase 2
Start date February 2013
Completion date September 2014

See also
  Status Clinical Trial Phase
Completed NCT03328520 - WILD 5 Wellness, A 30-Day Intervention N/A
Completed NCT01720472 - Implementing a Physical and Cognitive Performance Assessment Cohort in the MURDOCK Study Community Registry and Biorepository
Withdrawn NCT03497299 - Combining rTMS With Varenicline to Prevent Smoking Lapse in Schizophrenia Phase 2